Sanofi (NASDAQ:SNY) Announces Quarterly Earnings Results, Beats Estimates By $1.35 EPS

Sanofi (NASDAQ:SNY) released its quarterly earnings data on Friday. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35, Zacks reports. The firm had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 20.59%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period last year, the firm earned $2.55 earnings per share.

Sanofi Stock Down 0.4 %

Shares of NASDAQ SNY opened at $54.10 on Monday. Sanofi has a one year low of $44.05 and a one year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The business’s fifty day moving average price is $56.08 and its 200-day moving average price is $51.78. The stock has a market capitalization of $137.30 billion, a PE ratio of 27.72, a P/E/G ratio of 1.55 and a beta of 0.60.

Wall Street Analysts Forecast Growth

SNY has been the subject of several recent research reports. Argus upped their price target on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.